in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
ScinoPharm and TaiGen sign API manufacturing deal
June 9, 2014 | Deepti Ramesh
ScinoPharm (Tainan, Taiwan), a company that develops and manufactures active pharmaceutical ingredients (APIs), says that it has signed a manufacturing contract with TaiGen Biotechnology (Taipei) for the clinical supply of the API for Burixafor, a new chemical entity discovered and developed by TaiGen. The API will be manufactured at ScinoPharm’s plant at Changshu, China. “Burixafor is a 100% in-house-developed product that can be used in the treatment of various intractable diseases. The cooperation between TaiGen and ScinoPharm will not only be a...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee